Sapuntsova S G, Mel'nikova N P, Deigin V I, Kozulin E A, Timoshin S S
Department of Dermatology, Central Research Laboratory, Far-Eastern State Medical University, Khabarovsk.
Bull Exp Biol Med. 2002 May;133(5):488-90. doi: 10.1023/a:1019874023845.
Proliferative activity of the epidermis in skin biopsy specimens from patients with atopic dermatitis before and during therapy with thymodepressin (immunosuppressant) was studied by immunohistochemical method (by expression of Ki-67 antigen). The number of Ki-67-positive keratinocyte nuclei in atopic dermatitis considerably surpassed the corresponding parameter in intact skin (32.46 +/- 3.06% vs. 8.73 +/- 1.28%, p<0.05). Two 10-day courses of thymodepressin (0.1% solution, 1 ml intramuscularly) for 30 days reduced the number of Ki-67-positive keratinocyte nuclei to 20.78 +/- 3.36%. Clinical improvement was also achieved (sleep became normal, itching decreased, erythema and desquamation also decreased or disappeared). These findings suggest that disorders in keratinocyte proliferation are an important component in the pathogenesis of atopic dermatitis and confirm high efficiency of thymodepressin in the treatment of this condition.
采用免疫组织化学方法（通过Ki-67抗原的表达）研究了特应性皮炎患者在使用胸腺抑制素（免疫抑制剂）治疗前及治疗期间皮肤活检标本中表皮的增殖活性。特应性皮炎中Ki-67阳性角质形成细胞核的数量显著超过正常皮肤中的相应参数（32.46±3.06%对8.73±1.28%，p<0.05）。两个为期10天的胸腺抑制素疗程（0.1%溶液，1毫升肌肉注射），共30天，使Ki-67阳性角质形成细胞核的数量降至20.78±3.36%。临床症状也有所改善（睡眠恢复正常，瘙痒减轻，红斑和脱屑也减轻或消失）。这些发现表明角质形成细胞增殖紊乱是特应性皮炎发病机制的重要组成部分，并证实了胸腺抑制素治疗该病的高效性。
